Evidence map›Paper›PMID 33140247›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Oral mucosal changes induced by adjuvant endocrine therapies in breast cancer patients: clinical aspects and proposal for management.

Caroline de Bataille, Marie Castellan, Carole Massabeau, Eva Jouve, Jean-Louis Lacaze, Vincent Sibaud, Emmanuelle Vigarios

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Dental prosthesis needs among breast cancer survivors: a Korean nationwide cross-sectional study with subgroup analysis by menopausal status at diagnosis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Caroline de BatailleDepartment of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse - Cedex, France.
Marie CastellanCHU Toulouse/Paul Sabatier University, Toulouse, France.
Carole MassabeauDepartment of Radiotherapy, Institut Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse - Cedex, France.
Eva JouveDepartment of Surgery, Institut Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse - Cedex, France.
Jean-Louis LacazeDepartment of Oncology, Institut Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse - Cedex, France.
Vincent SibaudDepartment of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse - Cedex, France.
Emmanuelle VigariosDepartment of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse - Cedex, France. vigarios.emmanuelle@iuct-oncopole.fr.ORCID https://orcid.org/0000-0002-3164-463X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adjuvant systemic treatments in breast cancer are indicated to reduce the risk of relapse. Their systemic side effects have been well documented and include menopausal symptoms such as impaired libido and vaginal dryness, increased risk of endometrial cancer, stroke, musculoskeletal symptoms including arthralgia and myalgia, osteopenia and fractures, skin rashes, and hypercholesterolemia. However, few articles have focused on the oral mucosal reactions related to adjuvant endocrine therapies (AETs) which clearly differ from those reported with chemotherapies or other targeted therapies used for breast cancer. AETs primarily expose patient to a higher risk of worsened periodontal health, salivary flow modifications, taste disturbance, and global deterioration of oral health-related quality of life. Although the rate of permanent discontinuation of AETs because of oral mucosal changes remains low, an interdisciplinary approach to evaluate oral health and to optimize oral supportive care appears essential to ensure an appropriate management and limit dose adjustment in treated patients. In this respect and based on our clinical experience, we propose recommendations to allow oncologists, nurses, and attending practitioners to implement appropriate measures rapidly and/or refer patients to dentists.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsChemotherapy, AdjuvantFemaleHumansMouth MucosaAntineoplastic Agents, HormonalAdjuvant endocrine therapyBreast cancerOral health-related quality of lifeOral mucosaPeriodontal health

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.